A journalist for more than two decades’ standing, Elizabeth has covered the pharma, biotech and medtech sectors in a variety of roles over the years. She moved to Scrip in 2023 from Vantage, where she specialised in cardiovascular therapies as well as obesity, diabetes and related metabolic disorders. Elizabeth has a degree in biochemistry from the University of Surrey.
Latest from Elizabeth Cairns
At a recent conference, executives from Boehringer and Amgen laid out their expectations for the future of obesity and how they intend to navigate the changes.
A single molecule was responsible for nearly three quarters of the Danish group’s DKK71.3bn ($10.3bn) Q3 revenues.
The UK group began more clinical trials last year than any other company, a new report from Citeline has found.
Unlike previous deals in this space which were mostly to do with discovering new compounds, the big pharma is paying $150m upfront to license a specific product.
The French major enjoys swift growth from Beyfortus among others, and is unworried by future competition.
The new company, Rhine Pharma, hopes to avoid the isotope production issues that have dogged other radiopharmaceutical developers.